DE60042687D1 - Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen - Google Patents

Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen

Info

Publication number
DE60042687D1
DE60042687D1 DE60042687T DE60042687T DE60042687D1 DE 60042687 D1 DE60042687 D1 DE 60042687D1 DE 60042687 T DE60042687 T DE 60042687T DE 60042687 T DE60042687 T DE 60042687T DE 60042687 D1 DE60042687 D1 DE 60042687D1
Authority
DE
Germany
Prior art keywords
expressing cells
cd11b
protein
containing vectors
introducing molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042687T
Other languages
German (de)
English (en)
Inventor
Claude Leclerc
Pierre Guermonprez
Daniel Ladant
Nicole Guiso
Nadia Khelef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Pasteur filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of DE60042687D1 publication Critical patent/DE60042687D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60042687T 2000-09-15 2000-09-15 Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen Expired - Lifetime DE60042687D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402562A EP1188446B1 (en) 2000-09-15 2000-09-15 Proteinaceous vectors for molecule delivery to CD11b expressing cells

Publications (1)

Publication Number Publication Date
DE60042687D1 true DE60042687D1 (de) 2009-09-17

Family

ID=8173866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042687T Expired - Lifetime DE60042687D1 (de) 2000-09-15 2000-09-15 Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen

Country Status (16)

Country Link
US (4) US20040001867A1 (enExample)
EP (2) EP1188446B1 (enExample)
JP (1) JP2004508065A (enExample)
KR (2) KR100879151B1 (enExample)
AT (2) ATE438409T1 (enExample)
AU (2) AU9385501A (enExample)
BR (1) BR0113915A (enExample)
CA (1) CA2422603A1 (enExample)
CZ (1) CZ2003726A3 (enExample)
DE (1) DE60042687D1 (enExample)
ES (1) ES2331348T3 (enExample)
HU (1) HUP0303126A3 (enExample)
PL (1) PL208864B1 (enExample)
PT (1) PT1188446E (enExample)
RU (1) RU2312143C2 (enExample)
WO (1) WO2002022169A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
ES2337694T3 (es) * 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
RU2517719C2 (ru) * 2008-05-29 2014-05-27 Трансжене Са Биомаркер для отбора пациентов и соответствующие способы
PL2233569T3 (pl) 2009-03-23 2015-02-27 Pasteur Institut Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
WO2019177669A1 (en) * 2017-11-03 2019-09-19 Mackay Memorial Hospital Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597605B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Nouveau materiau pour chromatographie d'affinite et son application a la separation et a la purification des antigenes proteiques des bacteries du genre bordetella
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5182211A (en) 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2638169B1 (fr) 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
NO175188C (no) 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
EP1715047A3 (en) * 1992-04-21 2008-08-27 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0831817B1 (en) * 1995-06-07 2001-03-14 Joel K. Swadesh Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent
WO1997035882A1 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
WO2001029220A2 (en) 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
ES2337694T3 (es) 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
US20070026022A1 (en) 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US8017132B2 (en) * 2009-03-23 2011-09-13 Institut Pasteur Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Also Published As

Publication number Publication date
HUP0303126A2 (hu) 2003-12-29
AU9385501A (en) 2002-03-26
PT1188446E (pt) 2009-11-10
WO2002022169A3 (en) 2002-11-21
JP2004508065A (ja) 2004-03-18
PL365743A1 (en) 2005-01-10
US20040001867A1 (en) 2004-01-01
US10004794B2 (en) 2018-06-26
WO2002022169A2 (en) 2002-03-21
US9370564B2 (en) 2016-06-21
EP1317282B1 (en) 2011-08-03
EP1188446A1 (en) 2002-03-20
KR100953364B1 (ko) 2010-04-20
ES2331348T3 (es) 2009-12-30
RU2312143C2 (ru) 2007-12-10
US20120214206A1 (en) 2012-08-23
HUP0303126A3 (en) 2004-10-28
KR20080059684A (ko) 2008-06-30
CA2422603A1 (en) 2002-03-21
US20050238637A1 (en) 2005-10-27
BR0113915A (pt) 2003-07-01
AU2001293855B2 (en) 2007-04-26
EP1317282A2 (en) 2003-06-11
EP1188446B1 (en) 2009-08-05
PL208864B1 (pl) 2011-06-30
HK1057989A1 (en) 2004-04-30
ATE518880T1 (de) 2011-08-15
CZ2003726A3 (cs) 2003-09-17
ATE438409T1 (de) 2009-08-15
KR20030055265A (ko) 2003-07-02
KR100879151B1 (ko) 2009-01-19
US20160375119A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
ATE518880T1 (de) Vektoren zur einführung von molekülen in cd11b exprimierende zellen
JP4629046B2 (ja) 反復配列タンパク質ポリマー活性剤結合体、方法および使用
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
CY1111491T1 (el) Βιολογικα δραστικες πρωτεϊνες που εχουν αυξημενη σταθεροτητα in vivo και/ή in vitro
IL226857A0 (en) Recombinant proteins that have undergone n-site glycosylation in prokaryotic cells
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
EA200500519A1 (ru) Полимерные конъюгаты с пониженными антигенными свойствами, способы их получения и применения
BR0211926A (pt) agentes para realçar a resposta imune
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
MX2010004687A (es) Derivados de queratina y metodos de hacer los mismos.
ATE420061T1 (de) 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
ATE453665T1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
CY1113871T1 (el) Διαδικασια παρασκευης γκαμπαπεντινης
ATE447612T1 (de) Fluoreszenzproteine
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
WO2010064132A8 (en) Mutants of staphylokinase carrying amino and carboxy-terminal extensions for polyethylene glycol conjugation
WO2007071684A3 (en) Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye and an amino silicone
BR0308180A (pt) protéinas de superfìcie de leptospira
WO2006010647A3 (en) Cosmetic composition comprising at least one surfactant having at least one point of molecular fragility, process therefor and uses thereof
Pille Elastin-like polypeptide particles for nanomedicine
BR0206690A (pt) Processos para a identificação da função do gene, para alteração da expressão de fatores celulares e para alteração do fenótipo de célula
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition